90%Confidence
3Views
FDASource
2026-05-02Date
Summary
Payless Compounders' semaglutide injectable is recalled for sterility concerns, a critical risk for patients and a major liability for the compounding pharmacy. This could disrupt the GLP-1 drug supply and increase regulatory oversight.
Actionable: Avoid investments in Payless Compounders and related compounding pharmacies until sterility protocols are verified.
AI Confidence: 90%
Data Points
firmPAYLESS COMPOUNDERS, LLC
classificationClass II
statusOngoing
distributionOR
productSemaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now